Aytu Drug Patent Portfolio
Aytu owns 3 orange book drugs protected by 6 US patents Given below is the list of Aytu's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8236285 | Buccal, polar and non-polar spray containing zolpidem | 07 Aug, 2032 | Active |
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes | 29 Mar, 2029 | Active |
| US9522191 | Modified release formulations containing drug—ion exchange resin complexes | 15 Jun, 2027 | Active |
| US7632517 | Buccal, polar and non-polar spray containing zolpidem | 01 Oct, 2017 | Expired |
| US5045552 | Pyridine derivatives having anti-ulcerative activity | 08 Nov, 2013 | Expired |
| US5045552 | Pyridine derivatives having anti-ulcerative activity | 08 May, 2013 | Expired |
Latest Legal Activities on Aytu's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aytu.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8062667 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2020 | US9522191 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 May, 2019 | US8062667 (Litigated) |
|
Expire Patent
Critical
| 15 Jan, 2018 | US7632517 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Dec, 2016 | US9522191 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Dec, 2016 | US9522191 |
|
Email Notification
Critical
| 01 Dec, 2016 | US9522191 |
|
Issue Notification Mailed
Critical
| 30 Nov, 2016 | US9522191 |
| Dispatch to FDC | 15 Nov, 2016 | US9522191 |
|
Application Is Considered Ready for Issue
Critical
| 14 Nov, 2016 | US9522191 |
|
Issue Fee Payment Received
Critical
| 11 Nov, 2016 | US9522191 |
|
Issue Fee Payment Verified
Critical
| 11 Nov, 2016 | US9522191 |
|
Email Notification
Critical
| 23 Sep, 2016 | US9522191 |
|
Electronic Review
Critical
| 23 Sep, 2016 | US9522191 |
|
Mail Notice of Allowance
Critical
| 23 Sep, 2016 | US9522191 |
Aytu's Family Patents
Aytu Drug List
Given below is the complete list of Aytu's drugs and the patents protecting them.
1. Aciphex Sprinkle
Aciphex Sprinkle is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5045552
(Pediatric)
| Pyridine derivatives having anti-ulcerative activity |
08 Nov, 2013
(11 years ago)
| Expired |
| US5045552 | Pyridine derivatives having anti-ulcerative activity |
08 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aciphex Sprinkle's drug page
2. Karbinal Er
Karbinal Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(3 years from now)
| Active |
| US9522191 | Modified release formulations containing drug—ion exchange resin complexes |
15 Jun, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Karbinal Er's drug page
3. Zolpimist
Zolpimist is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8236285 | Buccal, polar and non-polar spray containing zolpidem |
07 Aug, 2032
(7 years from now)
| Active |
| US7632517 | Buccal, polar and non-polar spray containing zolpidem |
01 Oct, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zolpimist's drug page